A trademark for the drug lovastatin.
References in periodicals archive ?
xx Advicor, Altocor, Altoprev, Caduet, cholestyramine, cholestyramine light, Colestid, Crestor, fenofibrate, gemfibrozil, Lescol, Lescol XL, Lipitor, Locholest, Lofibra, Lopid, lovastatin, Mevacor, Niaspan, Pravachol, Pravigard PAC, Prevalite, Questran, Questran Light, Tricor, Welchol, Zetia, Zocor Depression 296.
TABLE: SIMILAR SOUNDING DRUG NAMES THAT COULD RESULT IN A MEDICATION ERROR Drug Name Confused With Abelcet Amphotericin B Accupril Aciphex Acetazolamide Acetohexamide Aciphex Aricept Aciphex Accupril Activase TNKase Actonel Actos Adderall Inderal Advicor Altocor Aggrastat Argatroban Adapted from Medication Safety Alert.
The $AVE program offers Altocor extended-release tablets, a well tolerated and highly effective cholesterol medication, at a price that can result in up to $1,000 a year in savings over comparable national brand-name products.
Operating under the banner SAVE (Select Altocor for Value and Effectiveness), the initiative is designed to provide needy patients with Altocor (lovastatin) extended-release tablets at a price that saves patients as much as $1,000 a year.
As part of this settlement, Andrx will pay Kos $6 million and has agreed to cease using the Altocor trademark for any of its products to avoid further confusion between Andrx's cholesterol product, Altocor, and Kos' highly differentiated cholesterol product, Advicor(R).
Initially the program for cash-paying customers is limited to Altocor, the company's first branded drug.
Andrx Corporation (Nasdaq:ADRX) announced that, effective June 19, 2004, Andrx will begin marketing its cholesterol-lowering brand product Altocor (lovastatin extended-release tablets) under the name Altoprev(TM).
a company with a history of marketing generics, is expected to debut Altocor, a new cholesterol-lowering drug that marks the company's first-ever branded drug.
The Company also announced today that, in order to avoid possible confusion in the marketplace, it is in discussions with the FDA to market its Altocor product under a new name.
Revenues for 2003 from brand products include a full year of sales of Altocor, which totaled $32.
This increase primarily resulted from net sales of Altocor of $10.
Altocor was also added to Medi-Cal, California's state Medicaid drug list.